Executive Interview – NeuroVive Pharmaceutical

Executive Interview – NeuroVive Pharmaceutical

Abliva — 2 videos in collection

More on this equity

NeuroVive is a leader in mitochondrial medicine, with one project in clinical Phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the company as it stands now and what the future holds for it.


You may also be interested in these:

Healthcare

Bitesize briefing - NeuroVive Pharmaceutical

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free